Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine
Praxis Precision Medicines announced positive topline results from its EMBRAVE Part A trial for elsunersen, showing a 77% placebo-adjusted reduction in seizures in pediatric patients with SCN2A DEE. The company's shares saw a significant surge following this news, alongside the FDA's acceptance of priority review for its New Drug Application for relutrigine, with a target action date of September 27, 2026. This positive news follows recent Q4 earnings where the company reported an EPS miss but highlighted a strong cash position and promising product pipeline, attracting reaffirmed "Buy" ratings and new "Outperform" coverage from analysts.
Praxis Precision reports positive Phase 1/2 elsunersen results; FDA sets PDUFA for relutrigine
Praxis Precision announced positive topline results from the EMBRAVE Part A study for elsunersen, showing a 77% placebo-adjusted seizure reduction and sustained efficacy. Additionally, the FDA has accepted its New Drug Application for relutrigine for priority review, setting a PDUFA target action date of September 27, 2026. Elsunersen was also well-tolerated with improvements reported in sleep, motor function, and other areas.
Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine
Praxis Precision Medicines reported positive early clinical results for elsunersen in treating SCN2A DEE, showing a 77% placebo-adjusted seizure reduction and sustained efficacy for up to one year, alongside functional improvements in pediatric patients. Additionally, the FDA granted priority review to relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, setting a PDUFA target action date of September 27, 2026. This dual announcement highlights significant progress in addressing severe childhood epilepsies with high unmet medical needs.
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial
Praxis Precision Medicine's stock rose after the company announced positive results from its EMBRAVE Part A trial for elsunersen, showing a 77% placebo-adjusted seizure reduction in pediatric patients with SCN2A DEE. The drug demonstrated a favorable safety profile, and most treated patients showed improvements in various developmental areas. Further results from the trial are expected to be presented at upcoming scientific meetings.
Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy
Praxis Precision Medicines announced positive results from the Embrave Part A trial of Elsunersen. The trial focused on patients with Scn2a Early-Onset Developmental and Epileptic Encephalopathy. This brief report from Reuters highlights the positive outcome of the clinical study, suggesting a potential advancement in treatment for this condition.
In a nine-patient Praxis trial, children had 77% fewer seizures
Praxis Precision Medicines (NASDAQ: PRAX) announced positive topline results from the EMBRAVE Part A trial for elsunersen in pediatric SCN2A early-onset developmental and epileptic encephalopathy (DEE), showing a 77% placebo-adjusted seizure reduction. The small, nine-patient trial also reported that 57% of patients achieved a 28-day seizure-free period, with sustained efficacy for up to one year in an open-label extension and no drug-related serious adverse events. Despite the promising early clinical signals, investors are advised to await pivotal data from the ongoing EMBRAVE3 study due to the trial's small size.
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines Inc. announced positive topline results from its EMBRAVE Part A trial for elsunersen, a treatment for pediatric patients with SCN2A early-seizure onset developmental and epileptic encephalopathy (DEE). The trial showed a 77% placebo-adjusted seizure reduction and improvements in sleep, motor function, muscle tone, and attention, with no drug-related serious adverse events. Elsunersen, an antisense oligonucleotide, aims to directly target the underlying cause of SCN2A-DEE and has received multiple regulatory designations.
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Praxis Precision Medicines announced positive topline results from the EMBRAVE Part A trial of elsunersen for pediatric SCN2A developmental and epileptic encephalopathy (DEE) patients. The trial showed a 77% placebo-adjusted seizure reduction, with 71% of treated patients achieving over 50% seizure reduction. Elsunersen also led to additional improvements in sleep, motor function, muscle tone, and attention, with no drug-related serious adverse events reported.
Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX
Aberdeen Group plc has acquired a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) worth approximately $39.79 million, representing 0.54% of the company. Other institutional investors have also adjusted their holdings in PRAX. Praxis reported a quarterly loss and analysts anticipate a full-year EPS of -$10.22, with the stock currently trading around $310.
PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Praxis Precision Medicines Inc.'s (PRAX) financials, focusing on revenue breakdown, profitability margins, and a comparison with competitors. It notes the company's N/A gross, operating, and net margins, and a negative Return on Equity (ROE) of -45.83%. Despite this, PRAX holds a leading market position with a capitalization of $8.64B, competing against companies like CYTK and NUVL.
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX
SG Americas Securities LLC reduced its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 26.2% in the fourth quarter, selling 3,531 shares and holding 9,965 shares valued at $2.94 million. Despite the institutional sell-off, other major funds increased their holdings, and institutional investors collectively own 67.84% of the company. Analysts maintain a "Moderate Buy" consensus rating for PRAX, with an average price target of $576.12, even after the company missed its quarterly EPS estimates.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced inducement grants of restricted stock unit awards covering 3,558 shares to eighteen new non-executive employees. These grants were made under the company's 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The awards will vest in four equal annual installments, contingent upon continued employment.
(PRAX) Risk Channels and Responsive Allocation
The article provides an AI-driven analysis for Praxis Precision Medicines Inc. (PRAX), indicating a near-term strong sentiment potentially leading to mid-term neutrality and a long-term positive bias. It identifies a mid-channel oscillation pattern and highlights a significant risk-reward short setup for the stock. The analysis includes specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, alongside multi-timeframe signal analysis.
18 new Praxis hires receive stock awards that vest over 4 years
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit (RSU) awards covering 3,558 shares to eighteen new non-executive employees under the 2024 Inducement Plan. These awards, granted on April 1, 2026, are inducements under Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, subject to continuous employment. This aligns with the company's recent milestones, including NDA submissions and a strong cash position.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards for 3,558 shares of common stock to eighteen new non-executive employees. These grants were made under the 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), as an inducement for their employment. The units will vest in four equal annual installments, contingent upon continued employment.
PRAX SEC Filings - Praxis Precision Medicines, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Praxis Precision Medicines, Inc. (PRAX) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, offering detailed insights into the company's regulatory disclosures and financial reporting. Stock Titan enhances these filings with AI-powered summaries and impact analysis. Recent filings cover a common stock offering, insider trading activities, positive Phase 3 results for ulixacaltamide in essential tremor, and the launch of a new ATM facility.
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800
Guggenheim has reiterated its "Buy" rating on Praxis Precision Medicines (PRAX.US) and maintained its target price of $800. This suggests a continued positive outlook from the firm regarding the company's stock performance and valuation.
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $525
Jefferies has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US) and increased its target price to $525. This indicates a strong positive outlook from the investment bank regarding the company's future performance.
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 13.4% - Time to Buy?
Praxis Precision Medicines (NASDAQ:PRAX) saw its stock rise by 13.4% on Tuesday, trading at approximately $313, though this occurred on light trading volume. Analysts rate the stock as a "Moderate Buy" with an average price target of $576.12, despite a recent EPS miss and projected full-year loss. Institutional ownership is high at nearly 67.8%, with several major investors increasing their stakes.
FDA fast-tracks Praxis drug for rare childhood epilepsy disorders
The FDA has accepted Praxis Precision Medicines' New Drug Application (NDA) for relutrigine for priority review, setting a PDUFA target action date of September 27, 2026. Relutrigine, intended for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), has Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations. If approved, it would be the first FDA-approved therapy for these conditions and would be eligible for a Pediatric Review Voucher.
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines announced that the FDA has accepted for priority review its New Drug Application (NDA) for relutrigine, targeting SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA set a PDUFA target action date of September 27, 2026. This potential approval marks a significant step towards providing the first disease-modifying therapy for children with these devastating and fatal conditions, supported by positive results from the EMBOLD study and several designations including Orphan Drug and Breakthrough Therapy.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Praxis Precision Medicines (NASDAQ:PRAX) has received a "Moderate Buy" consensus rating from 19 brokerages, with an average 12-month price target of $576.12. The biopharmaceutical company recently reported a missed quarterly EPS of ($3.50), but analysts anticipate a full-year EPS of -10.22. Institutional investors hold a significant portion of the shares, with several firms increasing their stakes in the last quarter.
Vanguard subsidiaries disaggregate holdings; Praxis (PRAX) shows 0 shares reported
The Vanguard Group filed an amended SCHEDULE 13G/A for Praxis Precision Medicines Inc (PRAX), reporting 0 shares beneficially owned and 0% of common stock as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, where Vanguard subsidiaries will now report their ownership separately, relying on SEC Release No. 34-39538. The filing indicates an administrative reallocation of reporting responsibility rather than a sale of shares.
Praxis Precision Medicines (NASDAQ:PRAX) Raised to Strong-Buy at Truist Financial
Truist Financial upgraded Praxis Precision Medicines (NASDAQ:PRAX) to a "strong-buy" rating, contributing to the stock's "Moderate Buy" consensus rating and a target of $576.12. Despite reporting a wider-than-expected quarterly EPS loss, the company's shares rose, supported by institutional investors and a positive outlook from several other research firms that have recently increased their price targets. Praxis Precision Medicines focuses on developing precision therapies for neurological and psychiatric conditions, with institutional ownership nearing 70%.
(PRAX) Movement as an Input in Quant Signal Sets
This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX) using quantitative signals, identifying a weak near and mid-term sentiment but a positive long-term outlook. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional risk-reward short setup and offers multi-timeframe signal insights.
5AM Venture Divests Entire Praxis Precision Medicines Position | February 2026 Filing - News and Statistics
5AM Venture Management has divested its entire stake in Praxis Precision Medicines, selling 170,000 shares in a transaction dated February 17, 2026. This sale valued the holding reduction at $9.01 million. Praxis Precision Medicines, a clinical-stage biopharmaceutical company focusing on CNS disorders, had a recent share price of $291.70 and a market capitalization of $8.1 billion, despite reporting a net loss for the trailing twelve-month period.
PRAX PE Ratio & Valuation, Is PRAX Overvalued
Praxis Precision Medicines Inc (PRAX) is currently considered overvalued, with a forward PS ratio of 8230.35, significantly higher than its five-year average. Its fair price is estimated to be between $36.67 and $171.82, making the current price of $303.38 about 76.57% overvalued. The company's P/S ratio is also 421.09% above the industry average, which is deemed unsustainable given a revenue growth of -100.00%.
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway
Praxis Precision Medicines (PRAX) has announced a significant cash balance projection of $926 million for 2025, which, combined with additional funds from a new financing deal, is expected to extend its operational runway into the second half of 2027. This financial clarity supports continued progress in its clinical trials, particularly for ulixacaltamide and elumapin for essential tremor and epilepsy, respectively. The company's enhanced financial position allows it to advance its pipeline and potentially achieve key clinical milestones without immediate funding concerns.
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway
Praxis Precision Medicines (PRAX) announced a pro forma cash balance of $926 million at the end of 2025, which is projected to fund operations into late 2027. This strong financial position follows a significant equity investment by Royalty Pharma and recent pipeline advancements, particularly for their lead candidate ulixacaltamide. The company plans to move ulixacaltamide into a Phase 3 study for essential tremor in the first half of 2025 and initiate a Phase 2b study for general anxiety disorder in 2026.
Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway
Praxis Precision Medicines (PRAX) concluded 2025 with $926 million in cash and investments, extending its cash runway into 2028 after an additional $621 million financing. The company submitted two New Drug Applications (NDAs) to the FDA for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation, and is advancing several other high-potential programs through its platforms. PRAX plans to nominate three new development candidates by mid-2026 for autism spectrum disorders and intellectual disabilities.
Algert Global LLC Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX
Algert Global LLC significantly increased its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by 483.3% in the third quarter, now owning 160,818 shares valued at $8.52 million. This move is part of a broader trend of institutional investors adjusting their positions in PRAX, which currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $576.12. Despite missing recent earnings estimates, the biopharmaceutical company, focused on neurological precision therapies, has seen its stock rise by 3.8%.
Cormorant Sells $9.31M in Praxis Shares, Holding Remains Top Position | 2026 Update - News and Statistics
Cormorant Asset Management reduced its stake in Praxis Precision Medicines by selling 50,000 shares for an estimated $9.31 million in Q4 2025. Despite this sale, Praxis Precision Medicines remains Cormorant's largest holding, valued at $280 million and representing 12.9% of its assets under management, with the total stake value increasing by $227 million. Praxis Precision Medicines is a biotechnology company focused on CNS disorders, with a market capitalization of $8.5 billion and $926 million in cash and investments at the end of 2025.
This biotech stock, which has surged by 700%, remains one of the leading holdings even after a $9.3 million sale in the previous quarter.
Cormorant Asset Management sold 50,000 shares of Praxis Precision Medicines (NASDAQ:PRAX) for $9.31 million in the fourth quarter of 2025, but the stock remains their largest holding, valued at $280 million. Praxis Precision Medicines shares have surged 700% over the past year, significantly outperforming the S&P 500. The company focuses on developing treatments for central nervous system disorders and is financially poised to transition from a development-stage company to a commercial pharmaceutical manufacturer.
HighVista Strategies LLC Has $5.04 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX
HighVista Strategies LLC has significantly increased its stake in Praxis Precision Medicines (NASDAQ:PRAX) by 41.2%, now holding 95,002 shares valued at $5.04 million. Other institutional investors like Bank of America and Algert Global also boosted their positions, contributing to 67.84% institutional ownership. Despite a recent EPS miss, analysts maintain a "Moderate Buy" rating with an average target price of $576.12.
Praxis Precision Medicines (PRAX) Is Down 5.4% After Major Institutional Buying and FDA Filings - Has The Bull Case Changed?
Praxis Precision Medicines (PRAX) has seen significant institutional investment from Driehaus Capital Management and Deerfield Management Company, totaling over US$346.79 million, following the company's FDA new drug applications for ulixacaltamide and relutrigine. These developments, along with a US$1.55 billion cash position, are reshaping the investment narrative towards a potential commercial model for its late-stage neuroscience candidates. Despite these positive indicators, the core clinical risk from pivotal epilepsy trials remains.
A Look At Praxis Precision Medicines (PRAX) Valuation After New Driehaus Investment And Recent FDA Filings
Praxis Precision Medicines (PRAX) is gaining attention following a new investment from Driehaus Capital Management and recent FDA submissions for two key drugs. The company's stock shows positive momentum despite short-term fluctuations, and its valuation suggests significant undervaluation compared to analyst targets, driven by late-stage CNS programs. However, its high Price-to-Book ratio compared to industry averages raises questions about how much future growth is already priced in.
Liquidity Mapping Around (PRAX) Price Events
This article provides a liquidity mapping analysis for Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It details specific institutional trading strategies, including long, breakout, and risk hedging, with defined entry points, targets, and stop losses. The analysis emphasizes a significant risk-reward short setup and offers real-time AI-generated signals and multi-timeframe insights for traders.
BTIG Maintains Buy on Praxis Precision Medicines (PRAX) March 2026
BTIG has reiterated a Buy rating on Praxis Precision Medicines (PRAX) as of March 9, 2026, despite recent trial results for X-TOLE2, stating that the readout has "no readthrough" for the stock. The firm did not issue a new price target, implying confidence in Praxis's broader pipeline beyond the specific trial outcome. Investors are advised to focus on company catalysts for potential upside, as the maintained rating is not an upgrade and does not guarantee immediate stock appreciation.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 2,931 shares to fourteen new non-executive employees on March 2, 2026. These grants were made under the 2024 Inducement Plan as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, contingent on continued employment.
Vanguard Group Inc. Increases Stock Position in Praxis Precision Medicines, Inc. $PRAX
Vanguard Group Inc. significantly increased its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by 4.2% in Q3, now owning 1,267,286 shares valued at $67.17 million. Institutional investors collectively hold 67.84% of the biopharmaceutical company, which focuses on precision therapies for neurological disorders. Analysts maintain a "Moderate Buy" rating with an average target price of $576.12, despite the company reporting a quarterly EPS miss and anticipated negative EPS for the current year.
Knott David M Jr Invests $1.48 Million in Praxis Precision Medicines, Inc. $PRAX
Knott David M Jr has invested $1.48 million in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) by purchasing 28,000 shares in the third quarter, representing 0.6% of his portfolio. Analysts show a "Moderate Buy" consensus with an average target price of $576.12, with some firms raising targets significantly. The company's stock trades near $310.71, has a market cap of $8.65 billion, and institutional ownership stands at 67.84%.
Is Praxis Precision Medicines (PRAX) Leaning on Equity Inducements to Reframe Its Post-Earnings Narrative?
Praxis Precision Medicines (PRAX) recently granted restricted stock unit awards to non-executive employees following a Q4 2025 earnings miss, which saw the company report significant net losses. This move, part of its 2024 Inducement Plan, is highlighted as a strategy to attract and retain talent despite financial underperformance, raising questions about execution risk, spending discipline, and shareholder dilution as the company funds an ambitious clinical agenda without current revenue. The article suggests investors should monitor how future trial outcomes support the case for absorbing these costs, emphasizing that while the grants don't alter the near-term clinical focus, they underscore financial challenges.
Is Praxis Precision Medicines (PRAX) Leaning on Equity Inducements to Reframe Its Post-Earnings Narrative?
Praxis Precision Medicines (PRAX) has issued restricted stock unit awards to 14 new non-executive employees following a Q4 2025 earnings report that missed both EPS and revenue estimates. These equity inducements are part of the company's strategy to attract and retain talent amidst financial underperformance and to support its ambitious late-stage CNS pipeline. Investors are urged to consider how these grants and future trial outcomes will affect the company's financial narrative, especially given current losses and future revenue projections.
Praxis Precision Medicines, Inc. $PRAX Shares Sold by TD Asset Management Inc
TD Asset Management Inc. significantly reduced its stake in Praxis Precision Medicines Inc. (NASDAQ:PRAX) by 36.1% in the third quarter, selling 23,054 shares and now holding 40,884 shares valued at $2.17 million. Despite other institutional investors increasing their holdings, the company reports a negative P/E ratio and recently missed quarterly EPS estimates. Analysts currently rate PRAX as a "Moderate Buy" with an average price target of $576.12, reflecting a mixed outlook with some high targets alongside sell ratings.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Recommendation of "Moderate Buy" from Analysts
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) has received an average "Moderate Buy" recommendation from nineteen analysts, with an average 12-month price target of $576.12. Despite missing quarterly EPS estimates, the biopharmaceutical company, focused on CNS disorders, shows significant institutional investment. The stock trades near $325, with a market capitalization of $9.05 billion.
A Look At Praxis Precision Medicines (PRAX) Valuation After Wider Full Year And Q4 Net Loss
Praxis Precision Medicines (PRAX) recently reported wider net losses for Q4 and the full year 2025, intensifying investor focus on cash burn and pipeline. Despite strong stock performance over the past year, the company is considered undervalued by analysts, with a narrative fair value of $449.13 due to its CNS pipeline, particularly in epilepsy treatments. The valuation hinges on significant future revenue growth and a shift to positive margins, but is subject to risks like trial underperformance or competition.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 2,931 shares to fourteen new non-executive employees on March 2, 2026. These grants, made under the 2024 Inducement Plan, serve as material inducements for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards will vest in four equal annual installments, contingent on continued employment.
Biotech Praxis gives 2,931 stock units to 14 new employees
Praxis Precision Medicines announced that its Compensation Committee granted 2,931 restricted stock units (RSUs) to fourteen new non-executive employees under the 2024 Inducement Plan. These awards were made on March 2, 2026, as inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments, contingent upon continued employment.
Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures
Praxis Precision Medicines is looking towards a future of significant growth as its precision neurology pipeline develops. The company's executives are optimistic about their strategy in the evolving life science industries, focusing on innovation and research in CNS. This article discusses Praxis's strategic outlook and pipeline maturity.
Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures
Praxis Precision Medicines is set to mature its precision neurology pipeline, anticipating a future with blockbuster potential. The article, published on March 3, 2026, discusses the company's strategies and innovations in the CNS space. It highlights candid conversations with C-suite leaders about evolving trends in the life science industry.
